MRD-Guided Surveillance in Operable Colon Adenocarcinoma (I-III)(SURVEILLANCE-I)

Launched by FUDAN UNIVERSITY · Mar 11, 2025

Keywords

ClinConnect Summary

The MRD-Guided Surveillance in Operable Colon Adenocarcinoma trial, also known as SURVEILLANCE-I, is studying how the presence of tiny amounts of cancer cells in the body after treatment can help predict whether colon cancer might come back. This study focuses on patients with stage I-III colon adenocarcinoma, which is a type of colorectal cancer that can be surgically removed. Researchers will collect blood samples from participants at various times—before and after surgery, and during follow-up visits over three years—to see if a blood test looking for cancer DNA can detect a recurrence of cancer sooner than traditional imaging tests like CT scans.

To be eligible for this trial, participants need to be between 18 and 80 years old, have a confirmed diagnosis of colon adenocarcinoma, and be able to undergo radical surgery without prior cancer treatments. The goal of the study is to see if monitoring these cancer cells can lead to earlier warnings about cancer returning, which could help doctors make better treatment decisions. If you or someone you know is interested in participating, it’s important to discuss this with a healthcare provider to understand more about the study and whether it’s a good fit.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age range: 18-80 years old, male or female not limited;
• • 2. Histologically confirmed colon adenocarcinoma (i.e. adenocarcinoma, including adenocarcinoma, mucinous adenocarcinoma, signet ring cell carcinoma, undifferentiated carcinoma; excluding adenosquamous cell carcinoma);
• • 3. Preoperative staging of stages I-III, without undergoing endoscopic ESD or EMR surgical resection;
• • 4. Not receiving chemotherapy, radiotherapy, targeted therapy, or other anti-tumor treatments;
• • 5. Radical surgery can be performed;
• • 6. ECOG score 0-1 points;
• • 7. The subjects voluntarily joined this study and signed an informed consent form, demonstrating good compliance and actively cooperating to return to the hospital for regular clinical follow-up diagnosis and treatment.
• Exclusion Criteria:
• • 1. Previously suffered from other malignant tumors (including non adenocarcinoma colorectal cancer);
• • 2. Pregnant and lactating women;
• • 3. According to the researchers' assessment, the patient also suffers from other diseases that may affect follow-up and short-term survival
• • 4. Subjects have other factors that may lead to the forced termination of this study, such as other serious diseases (including mental illness, infectious diseases, fever ≥ 38 ℃, etc.) requiring combined treatment, serious laboratory examination abnormalities, accompanied by family or social factors, which will affect the safety of subjects, or the collection of data and samples.